Merck Reports Overall Survival Improvement in Phase 3 TroFuse-015 Trial
Key Facts
Merck said on November 20, 2026, that the pivotal Phase 3 TroFuse-015 trial met its primary endpoint, with the final analysis showing a statistically significant and clinically meaningful improvement in overall survival among patients with advanced gastroesophageal adenocarcinoma. The study compared the investigational drug sacituzumab tirumotecan with physician’s choice of treatment. The company said the overall survival improvement was generally consistent across subgroups with different levels of TROP-2 protein expression. However, the positive result was confined to the primary endpoint, as the treatment did not meet the secondary progression-free survival endpoint. The announcement puts the overall survival results at the center of the news while underscoring that the trial’s results were not positive across all its specified measures.
The trial targeted patients with advanced unresectable or metastatic gastroesophageal adenocarcinoma, including tumors of the stomach, gastroesophageal junction and esophagus. Participants had received two or more lines of systemic therapy before entering the study, placing the drug in a later line of treatment. The study enrolled 473 patients and randomly assigned them to sacituzumab tirumotecan or physician’s choice of treatment. Comparator options included trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. The comparison was therefore against multiple treatment options, one of which was selected by the physician, rather than a single drug for all participants.
The investigational drug is an antibody-drug conjugate targeting TROP-2 protein and is licensed to Merck by Kelun-Biotech. Separately, the objective response rate showed a nominal improvement in favor of the drug, according to the company. But Merck said this analysis was not formally tested under the prespecified analysis plan. The result therefore remains a nominal response finding, while overall survival was the primary endpoint the company said the trial met. Progression-free survival, assessed by an independent blinded review, did not reach the prespecified success threshold for a secondary endpoint.
Merck said the safety profile was consistent with that observed in previous studies and that no new safety signals emerged. This comes alongside the overall survival result, but does not change the failure on the progression-free survival endpoint or the nominal nature of the response-rate analysis. Across the drug development program, the company described TroFuse-015 as the second positive Phase 3 study in the TroFuse program. The program includes 18 ongoing global Phase 3 trials across multiple tumor types, according to Merck’s announcement on November 20, 2026. These figures place the study within a broader drug development program, without in themselves specifying a filing timeline or commercial outlook.
The company said the data would be presented at a forthcoming medical meeting and shared with regulatory authorities, without specifying a date for either. The announcement did not disclose a regulatory filing timeline or provide revenue forecasts. The next stated step is therefore to present the results and discuss them with regulators, while details on timing and the subsequent path remain unspecified. A medical presentation would provide an opportunity to present the study data at an upcoming meeting, while Merck also said it would share them with the relevant authorities. The announcement gave no further details on the meeting date or the nature of the regulatory discussions.
The TAGS trial provides historical context for an approved treatment in this field, but it was a separate study and does not represent a result from TroFuse-015. In U.S. Food and Drug Administration data on Lonsurf, median overall survival was 5.7 months among patients who received the treatment, compared with 3.6 months with placebo, with a hazard ratio of 0.69. These figures are from the TAGS trial, which supported Lonsurf’s approval, and do not measure the performance of Merck’s investigational drug. Across the U.S. population, the U.S. National Cancer Institute estimated 31,510 new cases of stomach cancer and 10,740 deaths from the disease in 2026. Five-year relative survival for cases classified as distant was also 8.1%, based on 2016–2022 data; these are population statistics, not individual outcomes or estimates for patients in the study.